AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
11.77
+0.29 (2.53%)
Dec 20, 2024, 4:00 PM EST - Market closed
AVITA Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for AVITA Medical stock have an average target of 16.5, with a low estimate of 12 and a high estimate of 21. The average target predicts an increase of 40.19% from the current stock price of 11.77.
Analyst Consensus: Hold
* Price targets were last updated on Nov 8, 2024.
Analyst Ratings
The average analyst rating for AVITA Medical stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Reiterates $9 → $12 | Hold | Reiterates | $9 → $12 | +1.95% | Nov 8, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $21 | Buy | Reiterates | $21 | +78.42% | Aug 9, 2024 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $21 → $9 | Buy → Hold | Downgrades | $21 → $9 | -23.53% | May 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $22 → $21 | Buy | Maintains | $22 → $21 | +78.42% | May 14, 2024 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 11, 2024 |
Financial Forecast
Revenue This Year
70.37M
from 50.14M
Increased by 40.34%
Revenue Next Year
107.52M
from 70.37M
Increased by 52.79%
EPS This Year
-1.81
from -1.40
EPS Next Year
-0.80
from -1.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 73.3M | 123.2M | 154.0M | |
| Avg | 70.4M | 107.5M | 134.5M | |
| Low | 67.1M | 94.6M | 121.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 46.2% | 75.0% | 43.3% | |
| Avg | 40.3% | 52.8% | 25.1% | |
| Low | 33.9% | 34.4% | 12.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.37 | -0.18 | -0.01 | |
| Avg | -1.81 | -0.80 | -0.26 | |
| Low | -2.34 | -1.75 | -0.86 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.